Roche launches new coronavirus antibody test
Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development of vaccines. In addition, a drug from the Basel-based pharma giant has proven to be effective against coronavirus-associated pneumonia.
Roche Headquarter in Basel
Roche is launching a new antibody test that will identify people to have already been infected with coronavirus whose bodies have now developed antibodies against the virus. The test should help in developing vaccines against SARS-CoV-2. In specific terms, the test focuses on antibodies against the spike protein of SARS-CoV-2. The majority of vaccine candidates are aimed at inducing an antibody reaction against the spike protein.
The test will initially be launched in countries that accept that CE mark of the European Union (EU), as detailed in a press release. Roche has, however, also applied for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The new test is actually the Basel-based pharma group’s twelfth coronavirus test in its testing portfolio.
In addition to launching a new test, Roche has also announced a success in relation to its drug Actemra/RoActemra. This has proven to be successful in treating patients suffering from pneumonia linked to a coronavirus infection. Patients that were administered Actemra/RoActemra in addition to the standard treatment, were 44 percent less likely to require ventilation or die as the disease progressed in comparison with those patients to receive only standard treatment and a placebo.
Share this article
You may also be interested in
The Basel-based startup Bottmedical has developed clear braces made from bio-based polymers. After closing a successful financing round, the company...Read More
China wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life...Read More